Healthcare Private Placement and M&A Transactions Review

Nuclidium: The company raised EUR 115 million of Series B venture funding in a deal led by Kurma Partners, Angelini Ventures, Wellington Partners and NEVA SGR on May 27, 2026. The company is a developer of novel radiopharmaceutical tracers designed for cancer diagnostics.

Garner: The company raised $100 million of Series E venture funding in a deal led by Index Ventures on May 28, 2026, putting the company’s pre-money valuation at $2.64 billion. The company is a developer of a healthcare data analytics platform designed to improve healthcare quality and affordability.

ClearNote Health: The company raised $52 million of Series D venture funding in a deal led by Mattias Westman on May 27, 2026, putting the company’s pre-money valuation at $222.5 million. The company is a developer of a proprietary epigenomic technology designed to detect high-mortality cancers at an early, more treatable stage through a standard blood draw.

Inherent: The company raised $50 million of venture funding in a deal led by Index Ventures and Radical Ventures on May 29, 2026. The company is a developer of artificial intelligence knowledge infrastructure software designed to provide enterprise AI agents with secure organizational context.

Veraxa: The company raised $50 million of venture funding from Lincoln Park Capital on May 28, 2026. The company is a developer of antibody-based therapeutics designed to deliver cancer therapies with minimized side effects.

H1: The company raised $40 million of venture funding in a deal led by CVS Health Ventures on May 28, 2026. The company is an operator of a healthcare data platform designed to help life sciences, health plans, and digital health companies identify providers, accelerate clinical trials, and support scientific and commercial decision-making.

Secretome Therapeutics: The company raised $30 million of Series A venture funding in a deal led by RA Capital Management on May 27, 2026, putting the company’s pre-money valuation at $345 million. The company is a developer of cell-based therapy designed for people who experience a heart attack and for patients with heart failure.

Triomics: The company raised $22 million of Series B venture funding in a deal led by Battery Ventures on May 27, 2026, putting the company’s pre-money valuation at $93 million. The company is a developer of an interconnectivity and workflow automation platform intended to accelerate clinical trials.

Waypoint Bio: The company raised $20 million of Series A venture funding in a deal led by Amplify Partners on May 28, 2026. The company is a developer of next-generation cell therapies for solid tumors using AI and spatial biology to design and optimize cell therapy candidates.

Neela Therapeutics: The company raised $13.8 million of venture funding in the form of convertible debt from Biogen on May 26, 2026. The company is a developer of a precision biotechnology and genetic medicines platform designed to advance targeted, next-generation therapies for pediatric central nervous system disorders.

Accuryn: The company raised $11.9 million of venture funding from Ceros. on May 29, 2026, putting the company’s pre-money valuation at $99 million. The company is a developer of a predictive monitoring system that measures urine output, core body temperature, and related patient signals to support critical care.

Kayak Therapeutics: The company raised venture funding from undisclosed investors on May 27, 2026. The company is an operator of a biotechnology business intended to harness clinical pathways and foundational research to develop innovative therapies for cancer patients.

Portal Biotechnologies: The company raised $11.7 million of venture funding from undisclosed investors on May 29, 2026. The company is a developer of a cell engineering platform designed to enable novel cell analytics and next-generation cell therapies.

REVELOHEALTH: The company raised an estimated $10 million of Series B venture funding from Accrete Health Partners and other undisclosed investors on May 27, 2026, putting the company’s pre-money valuation at $154 million. The company is a developer of a healthcare data intelligence platform for claims repricing, claims operations, and healthcare analytics.

Psilera: The company raised $8.8 million of venture funding from undisclosed investors on May 28, 2026. The company is a developer of psychedelic-based drugs designed for neurological therapeutics.

SOND: The company raised $7 million of venture funding from E14 Fund, Crosslink Capital and Ubiquity Ventures on May 27, 2026. The company is a developer of a sleep wellness platform.

iFAST: The company raised GBP 5 million of venture funding in a deal led by Meridian Health Ventures on May 27, 2026. The company is an operator of a medical research business intended to reduce the threat of antimicrobial resistance.

OncoSynergy: The company raised $6.6 million of venture funding from undisclosed investors on May 26, 2026. The company is a developer of immunotherapies for cancer patients.

Klothea Bio: The company raised $5.9 million of venture funding in the form of convertible debt in a deal led by Longevitytech.fund on May 28, 2026. The company is a developer of mRNA-based therapeutics intended for addressing age-related disease mechanisms.

THERAtRAME: The company raised EUR 4.3 million of venture funding in a deal led by Qbic Fund on May 27, 2026, putting the company’s pre-money valuation at EUR 5.6 million. The company is a developer of a drug discovery platform designed to discover TM-enzyme-type molecules against cancer.

ReVision Implant: The company raised EUR 4 million of venture funding from undisclosed investors on May 26, 2026. The company is a developer of a neurotechnology platform designed to restore functional vision for blind people.

CancerIQ: The company raised $4.3 million of venture funding in the form of convertible debt from OSF Ventures on May 26, 2026. The company is a developer of precision health technology designed to help doctors identify and manage patients at high risk for cancer.

Rua Diagnostics: The company raised $3.6 million of venture funding from undisclosed investors on May 27, 2026. The company is a developer of a non-invasive diagnostic device intended for early detection and monitoring of diseases through breath analysis.

ProxyBio: The company raised $3.5 million of venture funding from GKCC on May 26, 2026. The company is a developer of a stem cell-derived 3D culture system designed for research and therapeutic development in complex diseases.

Vaccine Company / Eli Lilly and Company: The company reached a definitive agreement to be acquired by Eli Lilly for $1.6 billion on May 26, 2026. The company is a developer of vaccine engineering technology designed to advance immunization against infectious diseases.

Curevo Vaccine / Eli Lilly and Company: The company reached a definitive agreement to be acquired by Eli Lilly for $1.5 billion on May 26, 2026. The company is a developer of a clinical-stage adjuvanted subunit vaccine intended to improve efficacy and broaden immune response.

LimmaTech Biologics / Eli Lilly and Company: The company reached a definitive agreement to be acquired by Eli Lilly for $780 million on May 26, 2026. The company is an operator of a clinical-stage biopharmaceutical business focused on vaccines for prevention of life-threatening infectious diseases.

Nagashima Medical Instruments / Alfresa Holdings: The company, a subsidiary of Nagashima Holdings, reached a definitive agreement to be acquired by Alfresa Holdings for an undisclosed amount on May 27, 2026. The company is a manufacturer of otorhinolaryngology medical devices designed to support diagnosis and treatment in ear, nose, and throat clinical settings.

Nimble Rx / Swoop: The company was acquired by Swoop, via its financial sponsor New Mountain Capital, through an LBO on May 26, 2026 for an undisclosed amount. The company is a developer of a pharmacy technology platform designed to modernize prescription management and delivery.